Effects of exercise intervention in breast cancer survivors: a meta-analysis of 33 randomized controlled trails

Guoqing Zhu¹
Xiao Zhang¹
Yulan Wang¹
Huizi Xiong²
Yinghui Zhao¹
Fenyong Sun¹

¹Department of Clinical Laboratory Medicine, ²Department of Dermatology, Shanghai Tenth People’s Hospital of Tongji University, Shanghai, People’s Republic of China

Background: Exercise is associated with favorable outcomes in cancer survivors. The purpose of this meta-analysis is to comprehensively summarize the effects of exercise intervention in breast cancer survivors.

Methods: A systematic search of PubMed, Elsevier, and Google scholar was conducted up to March 2015. References from relevant meta-analyses and reviews were also checked.

Results: Thirty-three randomized controlled trials were included in this meta-analysis, including 2,659 breast cancer survivors. Compared with the control group, quality of life was significantly improved in exercise intervention group, especially in mental health and general health subscales of short form 36 questionnaire, as well as emotion well-being and social well-being subscales of the Functional Assessment of Cancer Therapy. Besides, exercise alleviated the symptoms of depression and anxiety in the exercise group. Furthermore, exercise was also associated with positive outcomes in body mass index, lean mass, and muscle strength. In addition, the serum concentration of insulin, insulin-like growth factor-II, and insulin-like growth factor binding protein-1 was significantly reduced in exercise intervention group. However, based on the current data of this meta-analysis, there were no significant differences in sleep dysfunction or fatigue between groups.

Conclusion: Our study suggested that exercise intervention was beneficial to breast cancer survivors. Therefore, exercise should be recommended to this patient group.

Keywords: exercise, quality of life, depression, BMI, insulin

Introduction
Breast cancer is one of the main causes of cancer deaths in women,¹ which was responsible for 23% of total cancer cases and 14% of cancer deaths.² With the improvements in early detection and treatment, the number of cancer survivors continued to increase, in which women with breast cancer accounted for 22% of total cancer survivors in 2012.³ However, the problems related to breast cancer and cancer treatment, such as cardiac toxicity of adjuvant systemic therapy,⁴,⁵ arm or shoulder problems, body image,⁶ change in social life, fear,⁷ and poorer quality of life⁸ were negatively associated with the overall well-being of breast cancer survivors.

A growing body of evidence indicated that exercise intervention results in beneficial outcomes in cancer patients. Some studies had suggested that exercise increased cardiorespiratory fitness,⁹ physical performance,¹⁰ and reduced overall mortality.¹¹ There were also studies demonstrating that exercise was associated with improvements in the symptom of depression,¹² body image, self-esteem,¹³ and quality of life,¹⁴⁻¹⁶ though some conclusions were not inconsistent in terms of fatigue.¹⁷
Previously, these effects of exercise intervention in breast cancer patients had been assessed in several meta-analyses and systematic reviews.\textsuperscript{18–22} However, some of them only summarized some of effects related to intervention,\textsuperscript{18,19} or compared the effects of group exercise with individual exercise.\textsuperscript{20} Others either only focused on one special symptom,\textsuperscript{21} or evaluated the efficacy of Tai Chi Chuan alone.\textsuperscript{22} Moreover, new evidences in recent years have not been included. Thus, we aim to comprehensively summarize the effects of exercise intervention on breast cancer patients based on the available data from randomized controlled trials.

**Methods**

**Literature search**

We searched PubMed, Elsevier, and Google Scholar up to March 2015. The reference lists of relevant systematic reviews and meta-analyses were also examined to identify additional studies. The search terms used in this meta-analysis were related to breast cancer (breast neoplasm, cancer, tumour, tumor, carcinoma) and exercise (exercise, physical activity, sport, weight training).

**Inclusion criteria**

Studies were considered eligible if they met the following criteria: 1) were written in English; 2) adopted a randomized controlled trial design, comparing exercise intervention group with control group (usual care, maintain current activity level, or waitlist); 3) included adults diagnosed with breast cancer; and 4) evaluated the effects of exercise in breast cancer patients.

Studies were excluded if: 1) included mixed cancer populations, including other types of cancer patients; 2) included other types of intervention (exercise intervention combined with diet); and 3) exercise merely focused on upper limb or arm.

**Data extraction**

Relevant data were independently extracted by GQ Zhu and X Zhang with a standard excel template, including 1) characteristics of the study and participants (first author, year of publication, mean age, sample size); 2) content of exercise intervention: exercise type, timing (before, during, or after treatment), and the frequency, intensity, and duration of intervention; 3) outcomes of intervention (quality of life, depression, anxiety, fatigue, muscle strength, body composition, physiological markers); and 4) assessment methods. Any disagreements were checked and discussed until a consensus was reached.

**Methodological quality assessment**

The methodological quality of the studies were independently assessed by two reviewers (GQ Zhu and YL Wang) using the Delphi criteria list,\textsuperscript{23} which is a set of nine criteria for quality assessment of randomized controlled trials. It was hard to blind the participants and providers in the interventional study. Therefore, participants blinding and provider blinding were not rated, and we only assessed the blinding of the outcome assessors. Each item was scored as yes (+) or no (−).

**Statistical analysis**

The outcomes were assessed if the data were available in at least two studies. For continuous outcomes, standardized mean differences with 95% confidence intervals (CIs) were calculated, with $P<0.05$ considered statistically significant. Statistical heterogeneity among studies was measured by $I^2$ test, in which values above 25% and 50% were considered as the indicative of moderate and high heterogeneity, respectively.\textsuperscript{24} A fixed-effect model was adopted when $I^2<50$%; otherwise, a random-effect model was used.

In the presence of heterogeneity, subgroup analysis was performed based on the measurement methods or the type of exercise. Besides, sensitivity analysis was carried out to evaluate the influence of a single study to the overall estimate. Publication bias was estimated through Begg’s test and Egger’s linear regression, with $P<0.10$ consumed as an indication of publication bias.\textsuperscript{25} All analyses were conducted using Review Manager Version 5.3 (Cochrane Collaboration, Copenhagen, Denmark) and Stata 12.0 (College Station, TX, USA).

**Results**

**Study selection**

A total of 3,429 records were identified from the database (Figure 1). After screening the titles and abstracts, the full texts of 161 articles were further reviewed for eligibility. Finally, 33 articles\textsuperscript{26–58} were included and assessed for methodological quality, with 128 articles excluded in which the aim, intervention type, or design of the study failed to meet the inclusion criteria.

**Characteristics of the exercise interventions**

There were 2,659 breast cancer patients, with the mean age of 54 (46.3–60.6) years (Table 1). The main types of exercise interventions reported in this meta-analysis were aerobic, resistance, and stretching exercises. Besides, there were also six studies on yoga intervention,\textsuperscript{28,39,42,45,50,52} two studies on tai chi chuan,\textsuperscript{35,55} and one on dancing.\textsuperscript{46} Twenty Five studies...
performed intervention after treatment,26,28,29,31–36,38,40,41,44,46–58 seven studies during treatment,20,27,32,37,43,45,51 and the remaining two studies before treatment.39,42 The duration of intervention lasted from 6 weeks to 12 months, with the frequency of intervention varying from two times a week to every day. The intensity of exercise also varied from low to vigorous in different situations, among which the moderate intensity was most frequently reported.

Methodological quality of included studies
We assessed 33 articles according to the Delphi criteria list, and seven criteria were examined in each of the study. In all, 14 studies met five criteria,26,30,35,38–41,51–54,56–58 12 studies more than five criteria,29,31,33,34,36,37,42,44,46,48–50 and the remaining 7 studies less than five criteria.27,28,32,43,45,47,55 Of these, 19 studies failed to conceal the allocation,26–28,32–34,38–40,43,45,47,52–58 and 22 studies did not blind the outcome assessor.27–28,30–32,35–36,38–41,43,47,53–55,57,58 Besides, 14 studies were not intention-to-treat analysis (Table 2).26–28,30,32,35,37,41,43,45,47,49,55,56

Pooled effect estimates for outcome measures
In this meta-analysis, we examined the effects of exercise intervention on quality of life, psychological outcomes, body composition, physical function and symptom, and physiological markers of breast cancer survivors. A total of 53 outcomes were evaluated, which were reported in at least two studies (Table 3).

Results of quality of life
The quality of life was reported as an outcome in 18 studies,26,30,31,36,37,41,42,45,46,51–58 among which 10 studies used the Functional Assessment of Cancer Therapy-Breast (FACT-B) and the Functional Assessment of Cancer Therapy—General (FACT-G) questionnaire,31,36,37,41,45,46,51,53–55 4 studies the Medical Outcomes Study Short Form health survey (SF-36) questionnaire,26,46,51,57 and two studies Treatment of Cancer-Quality of Life questionnaire (EORTCQoLC30).42,58 The other 4 studies used SF-12 health survey (SF-12),52 the Functional Assessment of Cancer Therapy—Anemia,30 the World Health Organization Quality of Life (WHOQOL-BREF),45 and the Cancer Rehabilitation Evaluation System-Short Form,56 respectively. We only pooled the outcomes that data could be extracted in at least two studies. Therefore, the data of 12 studies, involving 15 quality life domains, were included in this meta-analysis.26,30,31,36,37,41,45,46,51,53–55,57

Measured by SF-36 or MOS SF-36, the exercise intervention significantly improved the mental health ($I^2=0\%$, $P=0\%$,
Table 1. Characteristics of 33 studies included in this meta-analysis

| Year | Study | Author            | Mean age (SD) Intervention/control | The exercise type of intervention/control | Number of subjects in intervention/control groups |
|------|-------|-------------------|------------------------------------|------------------------------------------|-----------------------------------------------|
| 2006 | 26    | Basen-Engquist et al | 55.7 (11.1)/54.4 (11.7) | Lifestyle program/standard care | 35/25 |
| 2007 | 27    | Battaglini         | 56.6 (16)/57.5 (23) | Cardiovascular, resistance, flexibility/control group | 10/10 |
| 2014 | 28    | Bower et al        | 54 (5.4) | Lyengar yoga/health education | 16/15 |
| 2011 | 29    | Cantarero-Villanueva et al | 48 (9)/49 (9) | Aerobic, resistance, neck–shoulder mobility, self-massage/usual care | 38/40 |
| 2007 | 30    | Courneya et al     | 49.5/49/49 | Aerobic/resistance/usual care | 82/78/82 |
| 2007 | 31    | Daley et al        | 51.6 (8.8)/50.6 (8.7)/51.1 (8.6) | Aerobic exercise/exercise-placebo/usual care | 34/46/38 |
| 2006 | 32    | Drouin et al       | 49.4 (7.0)/51.9 (10) | Walking/placebo stretching | 8/13 |
| 2009 | 33    | Irwin et al        | 56.5 (9.5)/55.1 (7.7) | Walking/usual care | 37/38 |
| 2009 | 34    | Irwin et al        | 56.5 (9.5)/55.1 (7.7) | Walking/usual care | 37/38 |
| 2011 | 35    | Janelsins et al    | 54.33 (10.64)/52.7 (6.67) | Tai Chi Chuan/no exercise control | 9/10 |
| 2008 | 36    | Milne et al        | 55.2 (8.4)/55.1 (8.0) | Aerobic, resistance, stretching; immediate/delayed exercise group | 29/29 |
| 2007 | 37    | Mutrie et al       | 51.3 (10.3)/51.8 (8.7) | Group exercise program: aerobic, resistance/usual care | 101/102 |
| 2007 | 38    | Nikander et al     | 52.5 (6.4)/51.3 (7.3) | Aerobic exercise/daily activity | 14/14 |
| 2009 | 39    | Rao et al          | NR | Yoga/brief supportive therapy | 45/53 |
| 2013 | 40    | Rogers et al       | 58.0 (6.1)/53.7 (13.9) | Aerobic, resistance/usual care | 15/13 |
| 2009 | 41    | Rogers et al       | 52 (15)/54 (8) | Walking/usual care | 21/20 |
| 2009 | 42    | Vadiraja et al     | NR | Yoga/brief supportive therapy | 45/53 |
| 2009 | 42    | Vadiraja et al     | NR | Yoga/brief supportive therapy | 45/53 |
| 2008 | 43    | Battaglini         | 57.5 (23)/56.6 (16) | Cardiovascular, stretching, resistance/control group | 10/10 |
| 2003 | 44    | Courneya et al     | 59 (5)/58 (6) | Cycle ergometers/no train | 24/28 |
| 2008 | 45    | Hwang et al        | 46.3 (7.5)/46.3 (9.5) | Stretching, aerobic exercise/self-shoulder stretching | 17/23 |
| 2005 | 46    | Sandel et al       | 59.7 (9.8)/59.5 (13.3) | Dance and movement program/a waitlist control group | 19/19 |
| 2007 | 47    | Moadel et al       | 55.11 (10.07)/54.23 (9.81) | Yoga/waitlist control group | 84/44 |
| 2003 | 48    | Fairey et al       | 59 (5)/58 (6) | Cycle ergometers/control group | 25/28 |
| 2005 | 49    | Schmitz et al      | 53.3 (8.7)/52.8 (7.6) | Weight training: immediate/delayed group trained | 42/43 |
| 2012 | 50    | Bower et al        | 54.4 (5.7)/53.3 (4.9) | Lyengar yoga/health education | 16/15 |
| 2009 | 51    | Cadmus et al       | 54.5 (8.2)/54 (10.9) | Home-based exercise program: phone guide/usual care | 25/25 |
| 2009 | 51    | Cadmus et al       | 56.5 (9.5)/55.1 (7.7) | Supervised exercise intervention/usual care | 37/37 |
| Timing          | Intensity                                      | Frequency                  | Duration | Outcomes                                                                 |
|-----------------|-----------------------------------------------|----------------------------|----------|--------------------------------------------------------------------------|
| Posttreatment   | Moderate                                       | NR                         | 6 months | Physical performance, QoL                                               |
| During treatment| Low-moderate: 40%–60% of predicted maximum exercise capacity | 2 times/week, ≤60 minutes | 21 weeks | Body composition, muscle strength                                        |
| Posttreatment   | Aeros: ACSM recommendations; resistance; 75% maximum load and increase | 3 times/week; 90 minutes | 8 weeks  | Inflammation-related gene expression, circulating markers of proinflammatory cytokine, salivary cortisol |
| Posttreatment   | Moderate-intensity (65%–85% of age-adjusted HR maximum and RPE of 12–13) | 3 times/week, 50 minutes  | 8 weeks  | Fatigue, cortisol, IgA salivary levels, α-amylace activity, cervical–shoulder range of motion |
| During treatment| AET: 60%–80% of VO2 max; RET: 60%–70% of their estimated one repetition maximum | 3 times/week              | Mean 17 (9–24) weeks | QoL, physical fitness, body composition, psychosocial functioning, fatigue |
| Posttreatment   | Moderate (60%–80% of measured maximum HRs)  3–5 times/week, 20–45 minutes | 3 times (supervised) +2 times (own)/week, 150 minutes | 6 months | Erythrocyte measures: RBC, HCT, HB, peak VO2 |
| Posttreatment   | Vigorous                                       | NR                         | 12 weeks | Insulin, IGF-1, IGFBP-3                                                 |
| Posttreatment   | Moderate                                       | 3 times/week, 60 minutes  | 12 weeks | Insulin, insulin-related molecules and cytokines, body composition       |
| During treatment| Moderate (50%–75% of age adjusted maximum HR) | 3 times/week, 45 minutes  | 12 weeks | QoL, depression, social physical anxiety, aerobic fitness                |
| Posttreatment   | Moderate                                       | 3 times/week, 15–35 minutes | 12 weeks | Feasibility, efficacy, physical performance                               |
| Before treatment| Vigorous                                       | Daily/60 minutes           | 6 months | QoL, inflammatory-related serum markers, cardiorespiratory fitness, muscle strength, body composition, fatigue, sleep |
| Posttreatment   | Moderate                                       | 150 minutes weekly aerobic, 2 sessions/week resistance | 3 months | Feasibility, healthy outcome: aerobic fitness, muscle strength, body composition, QoL, sleep |
| Posttreatment   | Moderate                                       | 150 minutes/week           | 12 weeks | The total caloric intake, fatigue, body composition, aerobic fitness     |
| Before treatment| NR                                             | Daily/60 minutes           | NR       | Peak oxygen consumption, QoL, fatigue, self-esteem, happiness, body composition |
| During treatment| 40%–60% of predicted maximum exercise capacity | 2 times/week, ≤60 minutes | 6 months | QoL, fatigue, ROM of shoulder, pain                                     |
| Posttreatment   | 70%–75% of maximal oxygen consumption in untrained subjects | 3 times/week, 15–35 minutes | 15 weeks | QoL, shoulder (ROM), body image                                           |
| During treatment| 50%–70% of the age-adjusted HR maximum         | 3 times/week, 50 minutes  | 5 weeks  |                                                                          |
| Posttreatment   | NR                                             | 2 times/weeks for 6 weeks, 1 time/week for 6 weeks, 50–60 minutes | 12 weeks | QoL, fatigue, distressed mood, spiritual well-being                     |
| Posttreatment   | NR                                             | 1.5-hour weekly classes    | 12 weeks | Fasting insulin, glucose, insulin resistance, IGFs, IGFBPs              |
| Posttreatment   | (70%–75%) of peak oxygen consumption           | 3 times/week, 15–35 minutes | 15 weeks | Body composition, insulin, glucose, IGF axis variables                  |
| Posttreatment   | Upper body: symptoms allowed; lower body: the most weight lift | 2 times/week, 60 minutes | 12/6 months | Vigor, depression, sleep, stress, physical performance                   |
| During treatment| Moderate-vigorous: 60%–80% of predicted maximal HR | 5 times/week, 30 minutes  | 6 months | Happiness, depression, anxiety, stress, self-esteem, QoL               |
| Posttreatment   | Moderate-vigorous: 60%–80% of predicted maximal HR | 5 times/week, 30 minutes  | 6 months | Happiness, depression, anxiety, stress, self-esteem, QoL               |

(Continued)
Table 1 (Continued)

| Year | Study | Author                  | Mean age (SD) | The exercise type of intervention/control | Number of subjects in intervention/control groups |
|------|-------|-------------------------|---------------|------------------------------------------|--------------------------------------------------|
| 2009 | 52    | Danhauer et al          | 54.3 (9.6)/57.2 (10.2) | Yoga class group/waitlist group           | 13/14                                             |
| 2012 | 53    | Hayes et al             | 51.2 (8.8)/52.2 (8.6)/53.9 (7.7) | Face-to-face/telephone exercise: aerobic strength intervention/ usual care | 67/67/60                                         |
| 2012 | 54    | Littman et al           | 60.6 (7.1)/58.2 (8.8) | Facility-based and home-based Vin/yoga intervention/waitlist control group | 27/27                                              |
| 2004 | 55    | Mustian et al           | 52/9          | Tai Chi Chuan/psychosocial support        | 11/10                                             |
| 2006 | 56    | Ohira et al             | 53.3 (8.7)/52.8 (7.6) | Weight training/control group             | 43/43 (39/40)                                    |
| 2012 | 57    | Sprod et al             | 54.33 (3.55)/52.7 (2.11) | Tai Chi Chuan exercise/standard support therapy | 9/10                                              |
| 2012 | 58    | Saarto et al            | 52.3/52.4      | Step aerobics class and circuit training class (supervised), endurance training (home)/control group | 263/237                                           |

Abbreviations: ACSM, American college of sports medicine; AET, aerobic exercise training; BMI, body mass index; HB, hemoglobin; HCT, hematocrit; HR, heart rate; IFGBP, insulin-like growth factor binding protein; IGF, insulin-like growth factor; IL, interleukin; NR, not reported; QoL, quality of life; RBC, red blood cell; RET, resistance exercise training; VO2 peak, peak oxygen consumption; IgA, immunoglobulin A; SD, standard deviation; ROM, range of motion; RPE, rating of perceived exertion.

Results of psychological outcomes

Pooled data from three studies indicated that the self-esteem score was higher in the intervention group ($P=0.006$, $95\%$ CI: 0.11, 0.62, Figure 2) and general health ($F=95\%$, $P=0.02$, $95\%$ CI: 0.70, 8.48, Figure 2) compared with the control groups. Besides, exercise was associated with a significant increase in emotion well-being ($F=2\%$, $P=0.0006$, $95\%$ CI: 0.12, 0.43, Figure 2) and social well-being subscales ($F=0\%$, $P=0.01$, $95\%$ CI: 0.19, 1.69, Figure 2) of the Functional Assessment of Cancer Therapy. The pooled results of five studies showed a significant increase in breast cancer subscale of the Functional Assessment of Cancer Therapy from exercise ($F=15\%$, $P=0.000001$, $95\%$ CI: 1.85, 4.04) (Table 3).$^{36,37,44,54,57}$ However, substantial heterogeneity was observed for some outcomes. There was no evidence of publication bias except for SF-36 role-emotion ($P=0.062$, Table 3).

However, substantial heterogeneity was observed for some outcomes. There was no evidence of publication bias except for SF-36 role-emotion ($P=0.062$, Table 3).

Results of body compositions

Seven parameters were included in this meta–analysis (Table 3). Body mass index (BMI) was examined in nine studies, and the pooled results indicated it reduced significantly with exercise ($F=0\%$, $P<0.00001$, $95\%$ CI: $-1.09$, $-0.47$, Figure 4).$^{34,35,37,38,40,41,44,49,54}$ Besides, the pooled results of four studies showed that exercise was associated with significant increase in lean mass compared with control groups ($F=57\%$, $P=0.04$, $95\%$ CI: 0.08, 2.25) (Table 3).

Similarly, body fat percentage ($F=57\%$, $P=0.02$, $95\%$ CI: $-3.33$, $-0.35$) and fat mass ($F=0\%$, $P=0.05$, $95\%$ CI: $-4.83$, $-0.04$) were significantly reduced in the exercise intervention groups (Table 3). However, there were no significant differences on waist circumference, hip circumference, and waist-to-hip ratio between intervention and control groups.

No publication bias was observed, with only moderate heterogeneity for lean mass and body fat (Table 3).
| Intervention/control | Training (home)/control group | Training class (supervised), endurance support therapy | Viniyoga intervention/waitlist | Usual care |
|----------------------|-------------------------------|------------------------------------------------------|---------------------------|-----------|
| Number of subjects in intervention/control groups | 263/237 | 9/10 | 67/67/60 | \ |

**Table 1**

| Study | Randomization | Conceal allocation | Similarity of baseline | Specified eligibility criteria | Blinding of outcome assessor | Point estimates and measures of reliability of primary outcome | Intention-to-treat analysis |
|-------|---------------|--------------------|------------------------|-------------------------------|-----------------------------|-----------------------------------------------------------|-----------------------------|
| Basen-Engquist et al, 2006 | + | - | + | + | + | + | - |
| Battaglini, 2007 | + | - | - | - | - | - | - |
| Bower et al, 2014 | + | - | + | + | + | + | - |
| Cantarero-Villanueva et al, 2011 | + | + | + | + | + | + | + |
| Courneya et al, 2007 | + | + | + | + | + | + | - |
| Daley et al, 2007 | + | + | + | + | + | + | + |
| Drouin et al, 2006 | + | - | + | + | + | + | - |
| Irwin et al, 2009 | + | - | + | + | + | + | + |
| Irwin et al, 2009 | + | - | + | + | + | + | + |
| Janssiis et al, 2011 | + | + | + | + | + | + | - |
| Meline et al, 2009 | + | + | + | + | + | + | + |
| Mutrie et al, 2007 | + | + | + | + | + | + | - |
| Nikander et al, 2007 | + | - | + | + | + | + | + |
| Rao et al, 2009 | + | - | + | + | + | + | - |
| Rogers et al, 2013 | + | + | + | + | + | + | - |
| Rogers et al, 2009 | + | + | + | + | + | + | - |
| Vadiraja et al, 2009 | + | + | + | + | + | + | + |
| Battaglini, 2008 | + | - | + | + | + | + | - |
| Courneya et al, 2003 | + | + | + | + | + | + | + |
| Hwang et al, 2008 | + | - | + | + | + | + | - |
| Sandel et al, 2005 | + | + | + | + | + | + | + |
| Moadel et al, 2007 | + | - | + | + | + | + | - |
| Fairey et al, 2003 | + | + | + | + | + | + | + |
| Schmidt et al, 2005 | + | - | + | + | + | + | - |
| Bower et al, 2012 | + | + | + | + | + | + | - |
| Cadmus et al, 2009 | + | + | - | + | + | + | + |
| Danhauer et al, 2009 | + | - | + | + | + | + | - |
| Hayes et al, 2012 | + | + | + | + | + | + | - |
| Littman et al, 2012 | + | + | + | + | + | + | - |
| Mustian et al, 2004 | + | - | + | + | + | + | - |
| Ohira et al, 2006 | + | + | + | + | + | + | - |
| Sprod et al, 2012 | + | + | + | + | + | + | + |
| Saarto et al, 2012 | + | + | + | + | + | + | + |
### Table 3 Meta-analysis of the effect of exercise intervention in breast cancer survivors

| Outcomes                          | Study | Number of subjects in intervention/control groups | $I^2$ (%) | $P$-value  | 95% CI          | Publication bias ($P$-value) |
|----------------------------------|-------|---------------------------------------------------|-----------|------------|-----------------|-----------------------------|
| The quality of life              | 10    | 125/116                                           | 18        | 0.03       | 1.04 (0.09, 2.00)| 0.917                        |
| (SF-36)                          |       |                                                   |           |            |                 |                             |
| Mental health                    | 4     | 125/116                                           | 95        | 0.95       | 0.11 (~3.54, 3.76)| 0.829                        |
| Role (physical)                  | 4     | 106/97                                            | 0         | 0.18       | 0.36 (~0.88, 0.16)| 0.289                        |
| Social function                  | 3     | 106/97                                            | 0         | 0.18       | 0.36 (~0.88, 0.16)| 0.289                        |
| Vitality                         | 3     | 106/97                                            | 61        | 0.16       | 1.35 (~0.53, 2.33)| 0.936                        |
| Pain                             | 3     | 106/97                                            | 98        | 0.33       | 2.58 (~2.65, 7.81)| 0.418                        |
| General health                   | 3     | 106/97                                            | 95        | 0.02       | 4.59 (0.70, 8.48)| 0.113                        |
| Role (emotion)                   | 3     | 106/97                                            | 13        | 0.6        | 0.10 (~0.46, 0.26)| 0.062                        |
| FACT-G                           | 6     | 237/200                                           | 87        | 0.08       | 6.02 (~0.73, 12.76)| 0.482                        |
| TACT: TOI                        | 2     | 54/57                                             | 96        | 0.23       | 13.04 (~8.13, 34.20)|                             |
| FACT-G: social well-being       | 8     | 343/316                                           | 0         | 0.01       | 0.94 (0.19, 1.69)| 0.889                        |
| FACT-G: function well-being      | 8     | 343/316                                           | 83        | 0.07       | 0.37 (~0.03, 0.77)| 0.589                        |
| FACT-G: emotion well-being       | 8     | 343/316                                           | 2         | 0.0006    | 0.27 (0.12, 0.43)| 0.889                        |
| FACT-G: physical well-being      | 8     | 343/316                                           | 88        | 0.15       | 1.53 (~0.57, 3.63)| 0.574                        |
| FACT-B subscale                  | 5     | 225/238                                           | 15        | <0.00001  | 2.96 (1.87, 4.04)| 0.906                        |
| FACT-B                           | 6     | 241/230                                           | 85        | 0.08       | 0.46 (~0.05, 0.97)| 0.235                        |
| Psychological outcomes           |       |                                                   |           |            |                 |                             |
| The Rosenberg Self-Esteem Scale  | 3     | 185/192                                           | 0         | 0.02       | 1.02 (0.18, 2.22)|                             |
| The 2-item Fordyce Happiness Measure | 2   | 87/90                                             | 0         | 0.66       | 1.34 (~4.64, 7.32)|                             |
| Depression                       | 6     | 378/373                                           | 2         | 0.001     | 2.08 (~3.36, ~0.80)| 0.236                        |
| Anxiety                          | 5     | 341/361                                           | 0         | <0.00001  | 3.17 (~4.76, ~1.58)| 0.200                        |
| Positive and negative affect scale| 3     |                                                   |           |            |                 |                             |
| PANAS negative                   | 3     | 142/150                                           | 76        | 0.02       | 5.31 (~9.92, ~0.71)|                             |
| PANAS positive                   | 3     | 142/150                                           | 0         | <0.0001   | 4.46 (2.48, 6.44)|                             |
| FACIT–Spiritual                  | 2     | 97/58                                             | 0         | 0.02       | 4.04 (0.76, 7.13)|                             |
| The Perceived Stress Scale       | 2     | 78/77                                             | 0         | 0.08       | 1.94 (~4.11, 0.22)|                             |
| Sleep dysfunction                |       |                                                   |           |            |                 |                             |
| The Pittsburgh Sleep Quality Index| 4    | 64/62                                             | 0         | 0.58       | 0.32 (~0.82, 1.46)| 0.082                        |
| Body composition                 |       |                                                   |           |            |                 |                             |
| Body mass index                  | 9     | 270/283                                           | 0         | <0.0001   | 0.32 (~1.16, 1.75)| 0.387                        |
| Lean body mass/lean mass         | 4     | 246/252                                           | 57        | 0.04       | 1.17 (0.08, 2.25)| 0.140                        |
| Body fat %                       | 5     | 267/272                                           | 57        | 0.02       | 1.84 (~3.33, ~0.35)| 0.376                        |
| Fat mass                         | 2     | 169/174                                           | 0         | 0.05       | 2.44 (~4.83, ~0.04)| 0.212                        |
| Waist-to-hip ratio               | 2     | 36/33                                             | 21        | 0.19       | 0.02 (~0.04, 0.01)|                             |
| Waist circumference              | 3     | 103/105                                           | 0         | 0.71       | 0.17 (~0.70, 1.03)|                             |
| Hip circumference                | 2     | 64/65                                             | 0         | 0.94       | 0.16 (~4.27, 3.94)|                             |
| Physical performance and function|       |                                                   |           |            |                 |                             |
| Fatigue                          | 10    | 841/800                                           | 83        | 0.69       | 0.30 (~1.16, 1.75)| 0.387                        |
| FACT–Fatigue subscale            | 3     | 120/134                                           | 46        | 0.17       | 2.75 (~1.22, 6.71)|                             |
| Fatigue Symptom Inventory        | 2     | 31/28                                             | 68        | 0.04       | 0.85 (~1.68, ~0.02)|                             |
| FACIT–Fatigue                    | 4     | 469/410                                           | 0         | 0.96       | 0.04 (~1.2, 1.27)|                             |
| Muscle strength                  | 5     | 235/236                                           | 48        | 0.0009    | 4.27 (1.76, 6.78)| 0.272                        |
| VO2 peak, mL/kg/min              | 2     | 185/192                                           | 52        | 0.21       | 0.68 (~0.38, 1.75)|                             |
| VO2 peak, mL/min                 | 2     | 185/192                                           | 46        | 0.19       | 0.06 (~0.03, 0.14)|                             |
| Physiological markers            |       |                                                   |           |            |                 |                             |
| IL-6                             | 4     | 46/45                                             | 70        | 0.36       | 1.01 (~1.14, 3.15)| 0.046                        |
| IL-6 change                      | 4     | 46/45                                             | 69        | 0.02       | 1.46 (0.27, 2.65)| 0.046                        |
| IL-8                             | 2     | 21/20                                             | 76        | 0.07       | 1.38 (~0.09, 2.86)|                             |
| Glucose                          | 3     | 71/77                                             | 0         | 0.35       | 0.27 (~0.29, 0.82)|                             |
| Glucose change                   | 3     | 71/77                                             | 99        | <0.00001  | 1.73 (1.36, 2.11)| 0.687                        |
| Insulin                          | 5     | 117/126                                           | 95        | 0.05       | 6.79 (~1.64, 0.06)|                             |
| Insulin change                   | 5     | 117/126                                           | 97        | 0.04       | 4.98 (~9.26, ~0.33)| 0.353                        |
| IGF-I                            | 5     | 119/126                                           | 99        | 0.47       | 7.46 (~12.94, 27.87)|                             |
| IGF-I change                     | 5     | 119/126                                           | 99        | 0.53       | 6.5 (~13.88, 26.89)| 0.957                        |
| IGF-II                           | 2     | 64/68                                             | 88        | 0.94       | 4.36 (~11.03, 11.75)|                             |

(Continued)
Study or subgroup | Experimental Mean | Control Mean | Weight | Mean difference IV, fixed, 95% CI | Mean difference IV, random, 95% CI |
|------------------|-----------------|-------------|--------|---------------------------------|---------------------------------|
| **SF-36: mental health** |
| Basen-Engquist et al., 2006a | 78.2 | 77.2 | 0.44 (−0.08, 0.96) |
| Cadmus et al., 2009b | 50.6 | 47.4 | 0.28 (−0.18, 0.73) |
| Cadmus et al., 2009c | 52.4 | 50.2 | 0.29 (−0.26, 0.80) |
| Spind et al., 2012* | 25 | 24.8 | 0.09 (−0.81, 0.99) |
| Sandal et al., 2015* | 52.3 | 43.9 | 0.04 (−0.01, 1.30) |
| Subtotal (95% CI) | 125 | 116 | 0.36 (0.11, 0.62) |

Heterogeneity: τ=13.5, df=4 (P=0.85); I²=0%
Test for overall effect: Z=2.77 (P=0.006)

Study or subgroup | Experimental Mean | Control Mean | Weight | Mean difference IV, fixed, 95% CI | Mean difference IV, random, 95% CI |
|------------------|-----------------|-------------|--------|---------------------------------|---------------------------------|
| **SF-36: general health** |
| Basen-Engquist et al., 2006a | 77.4 | 67.1 | 10.30 (8.98, 11.62) |
| Cadmus et al., 2009b | 50.8 | 51.7 | −1.70 (−5.62, 2.22) |
| Cadmus et al., 2009c | 51.4 | 49.2 | 2.40 (−2.23, 7.03) |
| Spind et al., 2012* | 24.7 | 19.3 | 5.48 (4.79, 6.17) |
| Subtotal (95% CI) | 106 | 97 | 4.59 (0.70, 8.48) |

Heterogeneity: τ=13.5; τ²=59.51, df=3 (P=0.0001); I²=95%
Test for overall effect: Z=2.31 (P=0.02)

Study or subgroup | Experimental Mean | Control Mean | Weight | Mean difference IV, fixed, 95% CI | Mean difference IV, random, 95% CI |
|------------------|-----------------|-------------|--------|---------------------------------|---------------------------------|
| **SF-36: emotional well-being** |
| McLeod et al., 2007a | 17.76 | 16.32 | 0.27 (−0.09, 0.64) |
| Oluttan et al., 2012b | 20.4 | 20.3 | −0.11 (−0.64, 0.42) |
| Courneya et al., 2003a | 21.5 | 20.3 | 0.37 (−0.17, 0.91) |
| Mine et al., 2008a | 19.6 | 16.7 | 0.85 (0.31, 1.39) |
| Rogers et al., 2009c | 20 | 21.1 | −0.05 (−0.66, 0.56) |
| Cadmus et al., 2009d | 21.1 | 20.5 | 0.21 (−0.34, 0.77) |
| Mulreel et al., 2007c | 20.1 | 18.9 | 0.19 (−0.27, 0.65) |
| Durante et al., 2009a | 20.8 | 18.2 | 0.28 (−0.02, 0.58) |
| Subtotal (95% CI) | 343 | 316 | 0.27 (0.12, 0.43) |

Heterogeneity: τ²=8.13, df=8 (P=0.42); P=2%
Test for overall effect: Z=3.43 (P=0.0006)

Study or subgroup | Experimental Mean | Control Mean | Weight | Mean difference IV, fixed, 95% CI | Mean difference IV, random, 95% CI |
|------------------|-----------------|-------------|--------|---------------------------------|---------------------------------|
| **SF-36: physical health** |
| McLeod et al., 2007a | 20.38 | 18.67 | 1.71 (−0.48, 3.91) |
| Oluttan et al., 2012b | 22.1 | 20.9 | 1.20 (−1.75, 4.15) |
| Courneya et al., 2003a | 21.1 | 20.7 | 0.40 (−1.51, 2.31) |
| Mine et al., 2008a | 20.7 | 19.4 | 1.30 (−0.73, 3.33) |
| Rogers et al., 2009c | 22.6 | 21.8 | 0.80 (−0.22, 3.86) |
| Cadmus et al., 2009d | 22.7 | 23.1 | −0.40 (−2.86, 2.06) |
| Cadmus et al., 2009e | 22.3 | 20.6 | 1.70 (−1.11, 4.51) |
| Mulreel et al., 2007c | 24.2 | 23.4 | 0.80 (−0.63, 2.23) |
| Haynes et al., 2012f | 23.1 | 20.4 | 2.70 (−1.78, 7.18) |
| Subtotal (95% CI) | 343 | 316 | 0.94 (0.19, 1.69) |

Heterogeneity: τ²=2.98, df=8 (P=0.94); P=0%
Test for overall effect: Z=2.47 (P=0.01)

Figure 2. The association between exercise intervention and quality of life in breast cancer survivors.

Notes: (A) SF-36 mental health, (B) SF-36 general health, (C) FACT emotion well-being, and (D) FACT social well-being.

Abbreviations: CI, confidence interval; FACT, Functional Assessment of Cancer Therapy; SD, standard deviation; SF-36, short form 36 questionnaire; df, degree of freedom.
Results of physical function and symptom

Muscle strength was reported in five studies, which indicated significant improvement ($F=48\%, P=0.0009$, 95% CI: 1.76, 6.78, Figure 5) in exercise intervention group. Besides, no significant improvement was showed on peak oxygen consumption, based on the data from two studies (Table 3). 27,30,34,40,41

Fatigue was assessed in 12 studies, the pooled results of which indicated that there was no difference on fatigue between the intervention and control groups (Figure 6). However, the effect of exercise on the symptom of fatigue still remained insignificant in both of the subgroups, except small reduction in Fatigue Symptom Inventory ($F=68\%, P=0.04$, 95% CI: −1.68, −0.02). No evidence of publication bias was detected in any of the results (Table 3).

Results of physiological markers

Eight physiological markers were examined in this meta-analysis (Table 3). When the data of postintervention were used, only insulin ($F=95\%, P=0.05$, 95% CI: −13.64, 0.06) and insulin-like growth factor binding protein (IGFBP)-1 ($F=46\%, P<0.00001$, 95% CI: −4.40, −1.91) were significantly reduced after exercise intervention. However, based on the changed serum concentration of physiological markers after intervention (postintervention minus baseline), exercise significantly reduced the serum concentration of insulin ($F=97\%$,

---

**Figure 3** The association between exercise intervention and depression and anxiety in breast cancer survivors.

**Notes:** (A) Depression and (B) anxiety.

**Abbreviations:** CI, confidence interval; SD, standard deviation; df, degree of freedom.

**Figure 4** The association between exercise intervention and body mass index in breast cancer survivors.

**Abbreviations:** CI, confidence interval; SD, standard deviation; df, degree of freedom.
Figure 5 The association between exercise intervention and muscle strength in breast cancer survivors. **Abbreviations:** CI, confidence interval; SD, standard deviation; df, degree of freedom.

### A

| Study or subgroup | Experimental | Control | Weight | Mean difference IV, fixed, 95% CI | Mean difference IV, random, 95% CI |
|-------------------|--------------|---------|--------|-----------------------------------|--------------------------------------|
| FACIT-fatigue     |              |         |        |                                   |                                      |
| Moade et al, 2007[^1^] | 36.56        | 10.85   | 45     | 34.77 13.58                      | 26 3.7% 1.79 (-3.42, 7.90)          |
| Littman et al, 2012[^2^] | 45           | 5.3     | 27     | 43.1 10.3                        | 27 5.7% 1.90 (-2.47, 6.27)          |
| Courneya et al, 2006[^3^] | 9.3          | 7.9     | 25     | 8.8 8.1                          | 28 5.6% (-0.50, -5.0)               |
| Milne et al, 2008[^4^] | 11.9         | 3.2     | 29     | 17.4 4.7                         | 29 10.4% (-0.50, -9.57, -15.43)    |
| Cantarero-Villanueva et al, 2011[^5^] | 11.9          | 4.0     | 32     | 4.9 1.3                          | 15 12.6% (-0.41, -0.00)             |
| Wadler et al, 2014[^6^] | 34           | 0.8     | 10     | 13 0.8                           | 7 7.5% 3.00 (-6.74, 12.74)          |
| Courneya et al, 2007[^7^] | 36.3         | 9.4     | 82     | 34.77 13.58                      | 26 2.7% 1.79 (-3.42, 7.90)          |
| Littman et al, 2012[^8^] | 45           | 3.4     | 27     | 43.1 10.3                        | 27 4.5% 1.90 (-2.47, 6.27)          |
| Bowler et al, 2014[^9^] | 34           | 1.8     | 16     | 4.9 1.3                          | 15 12.3% (-0.50, -0.00)             |
| Cordero et al, 2013[^10^] | 4.2       | 0.3     | 82     | 34.77 13.58                      | 26 2.7% 1.79 (-3.42, 7.90)          |
| Mutrie et al, 2007[^11^] | 40.3         | 1.0     | 82     | 34.77 13.58                      | 26 2.7% 1.79 (-3.42, 7.90)          |
| Hayes et al, 2012[^12^] | 41.7         | 10.2493 | 67     | 41.8 10.0647                      | 60 7.3% -1.40 (-8.47, 2.07)          |
| Danhauer et al, 2009[^13^] | 39.8         | 12.4    | 13     | 32.6 15.5                        | 14 1.0% 3.00 (-6.74, 12.74)         |
| Sarito et al, 2012[^14^] | 2.4         | 9.0697  | 263    | 2.4 8.5958                       | 237 11.7% 0.00 (-1.55, 1.55)         |
| Subtotal (95% CI) | 809          |         |        | 765 100% -0.06 (-1.42, 1.30)     |                                      |
| **Total (95% CI)** | 809          |         |        | 765 100% -0.06 (-1.42, 1.30)     |                                      |
| **Test for overall effect:** | Z=3.33 (P=0.0009) | | | | |

### B

| Study or subgroup | Experimental | Control | Weight | Mean difference IV, fixed, 95% CI | Mean difference IV, random, 95% CI |
|-------------------|--------------|---------|--------|-----------------------------------|--------------------------------------|
| Yoga              |              |         |        |                                   |                                      |
| Moade et al, 2007[^15^] | 36.56        | 10.85   | 45     | 34.77 13.58                      | 26 2.7% 1.79 (-3.42, 7.90)          |
| Littman et al, 2012[^16^] | 45           | 5.3     | 27     | 43.1 10.3                        | 27 4.5% 1.90 (-2.47, 6.27)          |
| Bowler et al, 2014[^17^] | 34           | 1.8     | 16     | 4.9 1.3                          | 15 12.3% (-0.50, -0.00)             |
| Danhauer et al, 2009[^18^] | 39.8         | 12.4    | 13     | 32.6 15.5                        | 14 1.0% 3.00 (-6.74, 12.74)         |
| Subtotal (95% CI) | 809          |         |        | 765 100% -0.06 (-1.42, 1.30)     |                                      |
| **Total (95% CI)** | 809          |         |        | 765 100% -0.06 (-1.42, 1.30)     |                                      |
| **Test for subgroup differences:** | not applicable | | | | |

### Figure 6

The association between exercise intervention and fatigue in breast cancer survivors. **Notes:** (A) Overall effect and (B) subgroup analysis based on the type of exercise intervention. **Abbreviations:** CI, confidence interval; FACIT, Functional Assessment of Chronic Illness Therapy; SD, standard deviation; df, degree of freedom.
The Functional Assessment of Cancer Therapy–Anemia, in our meta-analysis, but not in general health scale of the SF-36. In this study, we only calculated the effect size of outcomes reported from at least two studies. Results showed that exercise was associated with significant improvements in quality of life, self-esteem, and the response attitude toward life. Besides, it alleviated the symptoms of depression and anxiety in breast cancer survivors. In addition to the beneficial outcome in body composition, exercise also increased muscle strength in the intervention groups. Furthermore, the serum concentration of some physiological markers, such as insulin, IGF-II, and IGFBP-1, was significantly reduced after exercise intervention.

In line with previous meta-analyses, the pooled results supported the evidences that exercise improved the quality of life in cancer patients. However, a significant improvement was shown in general health subscale of SF-36 in our meta-analysis, but not in general health scale of the Functional Assessment of Cancer Therapy.

Similarly, a statistically significant increase was only detected in the social function and emotion function scales of the SF-36, with a mean difference of 6.30 (95% CI: 6.04–6.64) in the social function scale and -5.24 (95% CI: -4.32–-6.16) in the emotion function scale. These improvements were found in the intervention groups, but not in the control groups.

According to the sensitivity analysis of the Functional Assessment of Cancer Therapy, the study by Mustian was identified as an outlier: the timing of intervention was during treatment in the study by Milne, whereas, the other studies were posttreatment. When excluding this outliers from analysis, the heterogeneity in the Functional Assessment of Cancer Therapy subscales (social well-being, function well-being, emotion well-being, physical well-being) decreased evidently (I²=0%, 27%, 20%, 0%, 8%, respectively).

The study by Basen-Engquist was also identified as an outlier, based on the sensitivity analysis of SF-36 subscales: in this study, the exercise intervention was lifestyle intervention, which encouraged participants to integrate activity into daily routine and perform activities they choose. When this study was excluded, the heterogeneity was evidently decreased in vitality (I²=0%), body pain of SF-36 (I²=0%), and general health (I²=86%).

In our current meta-analysis, we only calculated the effect size of outcomes reported in at least two studies. Therefore, the data of life quality measured by the Functional Assessment of Cancer Therapy–Anemia, the European Organization...
for the Research and Treatment of Cancer-Quality of Life (EORTCQoL C30 questionnaire), 42,58 the Cancer Rehabilitation Evaluation System-Short Form, 36 and the WHOQOL-BREF were not pooled. 45 Even though all the five studies favored exercise intervention, only three of them reported a clinical significant improvement in quality of life on breast cancer survivors, 42,43,56 and the results in other two studies failed to reach statistical significance. 30,58

We observed a significant improvement in depression, anxiety, and self-esteem in breast cancer patients, which were frequently reported in pervious meta-analyses and systematic reviews with mixed cancer patients. 59,61–64 We also discovered that the attitude toward life in intervention group was more positive than control group. The positive attitude played a critical role in the emotion well-being, which might have some correlation with improved quality of life in breast cancer survivors.

There was no clinical significant change on the symptom of fatigue between groups, based on the pooled results in our meta-analysis, which was consistent with a previous meta-analysis. 65 However, physical activity was reported to be associated with improvement on the symptom of fatigue in several meta-analyses, both breast and other cancer survivors. 19,59,62,65,66

In the subgroup analysis based on the measurement methods, a significant decrease of fatigue was only observed in the Fatigue Symptom Inventory. We then stratified the results by the types of intervention, the results of which still remained insignificant. Even yoga, a “mind–body” exercise, had no significant effect on fatigue, which had been suggested to be associated with a moderate reduction of fatigue in a previous study. 67 We further performed sensitivity analysis, the results of which indicated the studies by Bower and Milne exerted substantial influence to the overall estimate. 28,36 However, when excluding the two studies, the fatigue level was increased in exercise intervention groups (F = 50%, P = 0.05, 95% CI: 0.02, 2.19), which had not been reported in previous meta-analysis. Given the current inconsistent conclusions, more researches are needed to further examine this effect.

Several system reviews and meta-analyses had suggested positive effects of exercise on peak oxygen consumption. 18,19,61,66 However, the pooled results of two studies observed no statistical significance change of peak oxygen consumption between groups, which might be attributed to the small size in our meta-analysis. Furthermore, owing to the lack of sufficient data, the outcomes, such as the 3-minute step test 32 and the figure-8 running test, 36 were not included in our meta-analysis, which also showed improvements compared with control groups.

Results indicated that exercise led to a statistically significant reduction in BMI and insulin. Each 5 kg weight gain might increase the breast cancer-specific mortality by 13% and all-caused mortality by 12%. 68 Besides, research showed that insulin was associated with BMI, and the increase of insulin was related to a twofold increased risk of breast cancer recurrence. 69 Thus, the decreased BMI and insulin from exercise might potentially contribute to a reduced risk of mortality and recurrence on breast cancer survivors.

Additionally, one study suggested that IGFBP-1 and IGFBP-5 as IGF-I antagonists might block mammary gland development. 70 However, pooled results showed that IGFBP-1 was significantly decreased in exercise intervention group, while the change of IGF-1 was insignificant. Contrary to previous results, two meta-analyses reported only IGF-I was reduced significantly, and no evidences of significant change were found in insulin, IGFBP-1, and glucose in both breast cancer patients or mixed cancer patients. 51,62 Therefore, given this inconsistency, we should treat the association between exercise and the change of physiological markers with caution, and more researches are needed before making a confirmed conclusion.

The sensitivity analysis of physiological markers identified two outliers: the study by Schmitz and Melinda, in which the duration of intervention lasted for 6 to 12 months, while the durations were 12 to 15 weeks in other studies. 34,59 Therefore, it is likely that the duration of exercise intervention is the source of heterogeneity among these results.

Limitations
In our meta-analysis, we only included published randomized control trails in two databases, though we further searched the relevant reference lists for potential articles, which may increase the risk of publication bias. Besides, there was a lack of consistency in terms of the outcomes reported and measurement methods among the studies. The outcomes, such as erythrocyte Levels, 32 salivary cortisol, 29 were reported in only one study respectively, and we, therefore, failed to calculate their effect sizes in present meta-analysis.

Similarly, the quality of life was measured by different methods, which made it difficult to combine the diverse outcomes. Therefore, we only pooled the outcomes of quality life components measured by the Functional Assessment of Cancer Therapy and SF-36, respectively, which were used in most of the studies.

Furthermore, some data could not be extracted in several studies, and we did not try to contact the authors for detailed information. In addition, we used the mean and
standard deviation of postintervention to calculate the effect sizes for most of the data, rather than the changes after the intervention, the results of which may be influenced by the differences at baselines.

**Implications for future research and practice**

The differences of intervention type, intensity, and duration might account for some variations in the effects of exercise, and we could have performed subgroup analysis based on these differences. However, it would lead to insufficient data to calculate the effect sizes of some outcomes. Therefore, future research should further explore the correlation between intervention effects and the exercise type, intensity, and duration.

Additionally, the survival outcomes in breast cancer survivors are likely to have some correlation with exercise intervention. However, the studies included in our current meta-analysis failed to examine this association. Therefore, it is recommended that future studies examine the effects of exercise intervention on survival outcomes and determine whether exercise will provide benefit to the survival outcomes.

Taken together, the present evidences support the idea that exercise intervention is beneficial to breast cancer survivors, although it fails to identify the optimal type, timing, and intensity of exercise intervention. In addition, previous studies demonstrated that it was feasible and safe for various cancer patients to exercise during treatment, without increasing the risk or exacerbating the symptoms of lymphedema. Nevertheless, some prospective longitudinal studies showed that the physical activity decreased during treatment. The frequency of exercise was also lower off-treatment than prediagnosis in breast cancer patients. Therefore, exercise intervention should be prescribed to breast cancer survivors, encouraging them to continue their established exercise habits or adopt a right type of exercise.

**Conclusion**

Though with some limitations, there are evidences that exercise was associated with beneficial outcomes in breast cancer survivors. Based on the results from 33 studies, exercise improved the quality of life and alleviated the symptoms of depression and anxiety in breast cancer survivors. There were also benefits on muscle strength and body composition. Besides, exercise intervention was associated with reduced serum concentration of insulin, IGF-II, and IGFBP-1. Therefore, on the basis of our current evidences, exercise should be recommended to breast cancer survivors.

**Acknowledgments**

This work was supported by the China National 973 Project (2012CB966904 and 20110402), the National Natural Science Foundation of China (81301689 and 81202958), the Yangfan Project of Shanghai Science and Technology Commission (14YF1412300), the Outstanding Youth Training Program of Tongji University (1501219080), and the Shanghai Tenth People’s Hospital Climbing Training Program (04.01.13024).

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. *CA Cancer J Clin*. 2014;64(1):9–29.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin*. 2011;61(2):69–90.
3. de Moor JS, Mariotto AB, Parry C, et al. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. *Cancer Epidemiol Biomarkers Prev*. 2013;22(4):561–570.
4. Short CE, James EL, Girgis A, Mcelduff P, Plotnikoff RC. Move more for life: the protocol for a randomised efficacy trial of a tailored-print physical activity intervention for post-treatment breast cancersurvivors. *BMC Cancer*. 2012;12(1):1–10.
5. Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. *Clin Cancer Res*. 2008;14(1):14–24.
6. Montazeri A, Vahdaninia M, Harihchi I, Ebrahimi M, Khaleghi F, Jarvandi S. Quality of life in patients with breast cancer before and after diagnosis: an eighteen months follow-up study. *BMC Cancer*. 2008;8:330.
7. Roundtree AK, Giordano SH, Price A, Suarez-Almazor ME. Problems in transition and quality of care: perspectives of breast cancer survivors. *Support Care Cancer*. 2011;19(12):1921–1929.
8. Nesvold IL, Reinertsen KV, Fossa SD, Dahl AA. The relation between arm/shoulder problems and quality of life in breast cancer survivors: a cross-sectional and longitudinal study. *J Cancer Surviv*. 2011;5(1):62–72.
9. Thorsen L, Skovlund E, Stromme SB, Hornslien K, Dahl AA, Fossa SD. Effectiveness of physical activity on cardiorespiratory fitness and health-related quality of life in young and middle-aged cancer patients shortly after chemotherapy. *J Clin Oncol*. 2005;23(10):2378–2388.
10. Ligibel JA, Meyerhardt J, Pierce JP, et al. Impact of a telephone-based physical activity intervention upon exercise behaviors and fitness in cancer survivors enrolled in a cooperative group setting. *Breast Cancer Res*. 2012;14(1):205–213.
11. Holick CN, Newcomb PA, Trentham-Dietz A, et al. Physical activity and survival after diagnosis of invasive breast cancer. *Cancer Epidemiol Biomarkers Prev*. 2008;17(2):379–386.
12. Basen-Engquist K, Hughes D, Perkins H, Shinn E, Taylor CC. Dimensions of physical activity and their relationship to physical and emotional symptoms in breast cancer survivors. *J Cancer Surviv*. 2008;2(4):253–261.
13. Ogunleye AA, Holmes MD. Physical activity and breast cancer survival. *Breast Cancer Res*. 2009;11(5):106.
14. Mandelblatt JS, Luta G, Kwan ML, et al. Associations of physical activity with quality of life and functional ability in breast cancer patients during active adjuvant treatment: the pathways study. *Breast Cancer Res Treat*. 2011;129(2):521–529.
15. Paxton RJ, Phillips KL, Jones LA, et al. Associations among physical activity, body mass index, and health-related quality of life by race/ethnicity in a diverse sample of breast cancer survivors. Cancer. 2012;118(16):4024–4031.

16. Vallance JK, Courneya KS, Plotnikoff RC, Yasz Y, Mackey JR. Randomized controlled trial of the effects of print materials and step pedometers on physical activity and quality of life in breast cancer survivors. J Clin Oncol. 2007;25(17):2352–2359.

17. Dimeo FC, Thomas F, Raabe-Menssen C, Propper F, Mathias M. Effect of aerobic exercise and relaxation training on fatigue and physical performance of cancer patients after surgery: a randomised controlled trial. Support Care Cancer. 2004;12(11):774–779.

18. Kim CJ. A meta-analysis of aerobic exercise interventions for women with breast cancer. West J Nurs Res. 2009;31(4):437–461.

19. McNeely ML, Campbell KL, Rowe BH, Klassen TP, Mackey JR, Courneya KS. Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ. 2006;175(1):34–41.

20. Floyd A, Moyer A. Group vs individual exercise interventions for women with breast cancer: a meta-analysis. Health Psychol Rev. 2009;4(1):22–41.

21. Meneses-Echavez JF, Gonzalez-Jimenez E, Ramirez-Velez R. Effects of supervised exercise on cancer-related fatigue in breast cancer survivors: a systematic review and meta-analysis. BMC Cancer. 2015;15:77.

22. Pan Y, Yang K, Shi X, Liang H, Zhang F, Lv Q. Tai chi chuan exercise for patients with breast cancer: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2015;2015:535237.

23. Verhagen AP, de Vet HC, de Bie RA, et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol. 1998;51(12):1235–1241.

24. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.

25. Hayashino J, Noguchi Y, Fukui T. Systematic evaluation and comparison of statistical tests for publication bias. J Epidemiol. 2005;15(6):235–243.

26. Basen-Engquist K, Taylor CL, Rosenblum C, et al. Randomized pilot test of a lifestyle physical activity intervention for breast cancer survivors. Patient Educ Couns. 2006;64(1–3):225–234.

27. Battaglini C. The effects of an individualized exercise intervention on body composition in breast cancer patients undergoing treatment. Sao Paulo Med J. 2007;125(1):22–28.

28. Bower JE, Greendale G, Crosswell AD, et al. Yoga reduces inflammatory signaling in fatigued breast cancer survivors: a randomized controlled trial. Psychooncology. 2014;43:20–29.

29. Cantarero-Villanueva I, Fernández-Lao C, Díaz-Rodriguez L, Fernández-de-las-Peñas C, del Moral-Avila R, Arroyo-Morales M. A multimodal exercise program and multimedia support reduce cancer-related fatigue in breast cancer survivors: a randomised controlled clinical trial. Eur J Integr Med. 2011;3(3):e189–e200.

30. Courneya KS, Segal RJ, Mackey JR, et al. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol. 2007;25(28):4396–4404.

31. Daley AJ, Crank H, Saxton JM, Mutrie N, Coleman R, Roafle A. Randomized trial of exercise therapy in women treated for breast cancer. J Clin Oncol. 2007;25(13):1713–1721.

32. Drouin JS, Young TJ, Beeler J, et al. Random control clinical trial on the effects of aerobic exercise training on erythrocyte levels during radiation treatment for breast cancer. Cancer. 2006;107(10):2490–2495.

33. Irwin ML, Alvarez-Reeves M, Cadmus L, et al. Exercise improves body fat, lean mass, and bone mass in breast cancer survivors. Obesity. 2009;17(8):1534–1541.

34. Irwin ML, Varma K, Alvarez-Reeves M, et al. Randomized controlled trial of aerobic exercise on insulin and insulin-like growth factors in breast cancer survivors: the Yale Exercise and Survivorship study. Cancer Epidemiol Biomarkers Prev. 2009;18(1):306–313.

35. Janelins MC, Davis PG, Wideman L, et al. Effects of Tai Chi Chuan on insulin and cytokine levels in a randomized controlled pilot study on breast cancer survivors. Clin Breast Cancer. 2011;11(3):161–170.

36. Milne HM, Wallman KE, Gordon S, Courneya KS. Effects of a combined aerobic and resistance exercise program in breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat. 2008;108(2):279–288.

37. Mutrie N, Campbell AM, Whyte F, et al. Benefits of supervised group exercise programme for women being treated for early stage breast cancer: pragmatic randomised controlled trial. BMJ. 2007;334(7592):517.

38. Nikander R, Sievanen H, Ojala K, Oivainen T, Kellokumpu-Lehtinen PL, Saarto T. Effect of a vigorous aerobic regimen on physical performance in breast cancer patients – a randomized controlled pilot trial. Acta Oncol. 2007;46(2):181–186.

39. Rao MR, Raghuram N, Nagendra HR, et al. Anxiolytic effects of a yoga program in early breast cancer patients undergoing conventional treatment: a randomized controlled trial. Complement Ther Med. 2009;17(1):1–8.

40. Rogers LQ, Fogleman A, Trammell R, et al. Effects of a physical activity behavior change intervention on inflammation and related health outcomes in breast cancer survivors: pilot randomized trial. Integr Cancer Ther. 2013;12(4):323–335.

41. Rogers LQ, Hopkins-Price P, Vicari S, et al. A randomized trial to increase physical activity in breast cancer survivors. Med Sci Sports Exerc. 2009;41(4):935–946.

42. Vadiraja HS, Rao MR, Nagarathna R, et al. Effects of yoga program on quality of life and affect in early breast cancer patients undergoing adjuvant radiotherapy: a randomized controlled trial. Complement Ther Med. 2009;17(5–6):274–280.

43. Battaglini CL. Effect of exercise on the caloric intake of breast cancer patients undergoing treatment. Braz Med Biol Res. 2008;41:709–715.

44. Courneya KS, Mackey JR, Bell GJ, Jones LW, Field CJ, Fairey AS. Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. J Clin Oncol. 2003;21(9):1660–1668.

45. Hwang JH, Chang HJ, Shim YH, et al. Effects of supervised exercise therapy in patients receiving radiotherapy for breast cancer. Yonsei Med J. 2008;49(3):443–450.

46. Sandel SL, Judge JO, Landry N, Faria L, Ouellette R, Majczak M. Dance and movement program improves quality-of-life measures in breast cancer survivors. Cancer Nurs. 2005;28:301–309.

47. Moadel AB, Shah C, Wylie-Rosett J, et al. Randomized controlled trial of yoga program on body composition in breast cancer patients undergoing treatment. J Clin Breast Cancer. 2003;3(3):167–170.

48. Fairey AS, Courneya KS, Field CJ, Bell GJ, Jones LW, Mackey JR. Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors: a randomized controlled trial. Cancer Epidemiol Biomarkers Prev. 2009;18(7):2121–2130.

49. Schmitz KH, Ahmed RL, Hannan PJ, Yee D. Safety and efficacy of weight training in recent breast cancer survivors to alter body composition, insulin, and insulin-like growth factor axis protein. Cancer Epidemiol Biomarkers Prev. 2009;18(1):1672–1680.

50. Bower JE, Garet D, Sternevieb B, et al. Yoga for persistent fatigue in breast cancer survivors: a randomized controlled trial. Cancer. 2012;118(15):3766–3775.

51. Cadmus LA, Salovey P, Yu H, Chung G, Kasl S, Irwin ML. Exercise and quality of life during and after treatment for breast cancer: results of two randomized controlled trials. Psychooncology. 2009;18(4):343–352.

52. Danhauer SC, Mihalko SL, Russell GB, et al. Restorative yoga for women with breast cancer: findings from a randomized pilot study. Psychooncology. 2009;18(4):360–368.
53. Hayes SC, Rye S, Disipio T, et al. Exercise for health: a randomized, controlled trial evaluating the impact of a pragmatic, translational exercise intervention on the quality of life, function and treatment-related side effects following breast cancer. *Breast Cancer Res Treat*. 2013;137(1):175–186.

54. Littman AJ, Bertram LC, Ceballos R, et al. Randomized controlled pilot trial of yoga in overweight and obese breast cancer survivors: effects on quality of life and anthropometric measures. *Support Care Cancer*. 2012;20(2):267–277.

55. Mustian KM, Katula JA, Gill DL, Roscoe JA, Lang D, Murphy K. Tai Chi Chuan, health-related quality of life and self-esteem: a randomized trial with breast cancer survivors. *Support Care Cancer*. 2004;12(12):871–876.

56. Ohira T, Schmitz KH, Ahmed RL, Yee D. Effects of weight training on quality of life in recent breast cancer survivors: The Weight Training for Breast Cancer Survivors (WTBS) study. *Cancer*. 2006;106(9):2076–2083.

57. Sprod LK, Janelsins MC, Palesh OG, et al. Health-related quality of life and biomarkers in breast cancer survivors participating in tai chi chuan. *J Cancer Surviv*. 2012;6(2):146–154.

58. Saarto T, Penttinen HM, Sievannen H. Effectiveness of a 12-month intervention on physical performance and quality of life in breast cancer patients and survivors – a meta-analysis. *Psychooncology*. 2011;20(2):115–126.

59. Duitj SF, Faber MM, Oldenburg HS, van Beurden M, Aaronson NK. Effectiveness of behavioral techniques and physical exercise on psychosocial functioning and health-related quality of life in breast cancer patients and survivors – a meta-analysis. *Psychooncology*. 2011;20(2):115–126.

60. Ferrer RA, Huedo-Medina TB, Johnson BT, Ryan S, Pescatello LS. Exercise interventions for cancer survivors: a meta-analysis of quality of life outcomes. *Ann Behav Med*. 2011;41(1):32–47.

61. Fong DY, Ho JW, Hui BP, et al. Physical activity for cancer survivors: meta-analysis of randomised controlled trials. *BMJ*. 2012;344:e70.

62. Speck RM, Courneya KS, Masse LC, Duval S, Schmitz KH. An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. *J Cancer Surviv*. 2010;4(2):87–100.

63. Schmitz KH, Holtzman J, Courneya KS, Masse LC, Duval S, Kane R. Controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. *Cancer Epidemiol Biomarkers Prev*. 2005;14(7):1588–1595.

64. Brown JC, Huedo-Medina TB, Pescatello LS, et al. The efficacy of exercise in reducing depressive symptoms among cancer survivors: a meta-analysis. *PLoS One*. 2012;7(1):e30955.

65. Brown JC, Huedo-Medina TB, Pescatello LS, Pescatello SM, Ferreir RA, Johnson BT. Efficacy of exercise interventions in modulating cancer-related fatigue among adult cancer survivors: a meta-analysis. *Am Association Cancer Res*. 2010;10(1158):1055–1060.

66. Spence RR, Heesch KC, Brown WJ. Exercise and cancer rehabilitation: a systematic review. *Can Treat Rev*. 2010;36(2):185–194.

67. Baffert LM, van Uffelen JG, Riphagen I. Physical and psychosocial benefits of yoga in cancer patients and survivors, a systematic review and meta-analysis of randomized controlled trials. *BMC Cancer*. 2012;12:559.

68. Nichols HB, Trentham-Dietz A, Egan KM, et al. Body mass index before and after breast cancer diagnosis: associations with all-cause, breast cancer, and cardiovascular disease mortality. *Cancer Epidemiol Biomarkers Prev*. 2009;18(5):1403–1409.

69. Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. *J Clin Oncol*. 2002;20(1):42–51.

70. Kleinberg DL, Wood TL, Furth PA, Lee AV. Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. *Endocrin Rev*. 2009;30(1):51–74.

71. Bertram LA, Stefanick ML, Saquib N, et al. Physical activity, additional breast cancer events, and mortality among early-stage breast cancer survivors: findings from the WHI Study. *Cancer Causes Control*. 2011;22(3):427–435.

72. Sternfeld B, Weltzien E, Quesenberry CP, et al. Physical activity and risk of recurrence and mortality in breast cancer survivors: findings from the LACE study. *Cancer Epidemiol Biomarkers Prev*. 2009;18(1):87–95.

73. Adamsen L, Quist M, Andersen C, et al. Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial. *BMJ*. 2009;339:b3410.

74. Ahmed RL, Thomas W, Yee D, Schmitz KH. Randomized controlled trial of weight training and lymphedema in breast cancer survivors. *J Clin Oncol*. 2006;24(18):2765–2772.

75. Andrykowski MA, Beacham AO, Jacobsen PB. Prospective, longitudinal study of leisure-time exercise in women with early-stage breast cancer. *Cancer Epidemiol Biomarkers Prev*. 2007;16(3):430–438.

76. Kwan ML, Sternfeld B, Ergas IJ, et al. Change in physical activity during active treatment in a prospective study of breast cancer survivors. *Breast Cancer Res Treat*. 2012;131(2):679–690.

77. Valenti M, Porzio G, Aielli F, et al. Physical exercise and quality of life in breast cancer survivors. *Inter J Med Sci*. 2008;5(1):24–28.